

UK NEQAS FOR H&I SCHEME 1B - HLA-B27 TESTING

HLA-B27 TYPING RESULTS OF SAMPLES 1B01&02/2018

DESPATCHED ON 06TH MARCH 2018

Summary of Results

Total tested (excl. Equivocal)	124	116	Donor HLA type	1B01/2018	HLA-A2, A-, B27, B47, Cw1, Cw6, DR103, DR7, DQ2, DQ7
Positive	121	111	Donor HLA type	1B02/2018	HLA-A3, A-, B27, B60, Cw1, Cw10, DR8, DR11, DQ4, DQ7
Negative	3	5			
NT/Equivocal	3	11			
% Positive	97.6%	95.7%			
% Negative	2.4%	4.3%			
Consensus	Positive	Positive			

Lab No	Result 1B01/2018	Result 1B02/2018	Date received	Date tested	Method	Primers and Probes	PCR-SSP	Detection system	High Resolution Typing HLA-B*27 alleles	Comments
									1B01/2018	1B02/2018
1	Positive	Positive	07-Mar	15-Mar	Molecular					
3	NT	NT	07-Mar	08-Mar	Serological					Poor sample quality
4	Positive	Positive	07-Mar	08-Mar	Serological					Both samples fall within our "equivocal" range. Patient samples would have been sent for confirmation by PCR.
7	Equivocal	Equivocal	09-Mar	14-Mar	Serological					
8	Positive	Positive	08-Mar	09-Mar	Serological					
9	Positive	Positive	07-Mar	07-Mar	Serological					
10	Positive	Positive	07-Mar	29-Mar	Molecular	Own design	Gel			
11	Positive	Positive	08-Mar	16-Mar	Molecular	Own design	Gel			
12	Positive	Positive	07-Mar	20-Mar	Molecular	Own design	Gel			
14	Positive	Positive	07-Mar	09-Mar	Molecular			B*27:03/05 group		B*27:09/27 group
15	Positive	Positive	08-Mar	19-Mar	Serological & Molecular					
17	Positive	Positive	07-Mar	08-Mar	Molecular	Commercial	Fluorescence			
19	Positive	Positive	07-Mar	08-Mar	Serological					
20	Positive	Positive	07-Mar	08-Mar	Serological					
21	Positive	Positive	08-Mar	08-Mar	Molecular	Own design	Gel			
22	Positive	Positive	07-Mar	08-Mar	Molecular	Commercial	Gel			
23	Positive	Positive	07-Mar	08-Mar	Molecular					
24	Positive	Positive	08-Mar	14-Mar	Molecular					
25	Positive	Positive	07-Mar	13-Mar	Molecular					
26	Positive	Positive	07-Mar	08-Mar	Molecular					
28	Positive	Positive	07-Mar	09-Mar	Molecular	Commercial	Gel, BAG reverse dot blot	B*27:03/05/09/09		B*27:05/09/27/46
29	Positive	Positive	08-Mar	12-Mar	Molecular					
31	Positive	Positive	07-Mar	13-Mar	Serological					
32	Positive	Positive	08-Mar	08-Mar	Serological	Commercial	SSOP			
34	Positive	Positive	07-Mar	08-Mar	Molecular					
35	Positive	Positive	07-Mar	08-Mar	Molecular					
37	Positive	Positive	09-Mar	15-Mar	Molecular					Sample 1B02 was initially typed as equivocal and was further tested to determine HLA-B27+ve status using our additional test method.
39	Positive	Positive	07-Mar	07-Mar	Molecular	Own design	Gel			
40	Positive	Positive	07-Mar	08-Mar	Serological					
41	Positive	Positive	07-Mar	14-Mar	Molecular	Own design	Gel			
42	Positive	Positive	08-Mar	13-Mar	Molecular				B*27:03/05/09/13/17/46/49/55/56/58/60/64/N72/37/4/78/80/82/84/87/88/90/93/94N/96/97/98/99/104/110/111/116/117/118/121/122/123/124/128/133/135/140/141/143/14/4146/150/151/152/155/156/158/159/162	B*27:05/09/27/46/78/125/151/154
45	Positive	Positive	07-Mar	12-Mar	Molecular	Own design	Gel	B*27:05/13		B*27:09
46	Positive	Equivocal	05-Mar	03-Sep	Serological					
47	Positive	Positive	08-Mar	08-Mar	Serological					
48	Positive	Positive	08-Mar	12-Mar	Molecular	Commercial	Gel			
54	Positive	Positive	07-Mar	09-Mar	Molecular	Own design	Gel			B*27:05.23, 27:18/23/29/75/95/157 are not detected by this method
55	Positive	Positive	03-Mar	20-Mar	Molecular					
57	Positive	Positive	07-Mar	07-Mar	Serological					
58	Positive	Positive	07-Mar	08-Mar	Molecular					
62	Positive	Positive	08-Mar	08-Mar	Molecular	Commercial	Gel			
65	Equivocal	Equivocal	13-Mar	15-Mar	Serological					Both of these samples had results in the 'grey zone'. Our laboratory procedure is to send samples to an external laboratory for testing by PCR.
66	Positive	Positive	09-Mar	13-Mar	Molecular					
67	Positive	Negative	06-Mar	07-Mar	Serological					
72	Positive	Positive	12-Mar	16-Mar	Molecular					
76	Positive	Equivocal	07-Mar	09-Mar	Serological					Result by flow cytometer fell within the manufacturer's recommended equivocal (indeterminate) range.
77	Positive	Positive	08-Mar	08-Mar	Serological					
78	Positive	Positive	08-Mar	14-Mar	Molecular	Commercial	Gel			
84	Positive	Negative	07-Mar	07-Mar	Serological					
84	Positive	Equivocal	08-Mar	08-Mar	Serological & Molecular					1B02/2018 would be sent for high resolution HLA-B27 testing. Flow on this sample was positive but needed PCR for confirmation.
85	Positive	Positive	07-Mar	09-Mar	Molecular					
86	Positive	Positive	07-Mar	12-Mar	Molecular					
90	Positive	Positive	12-Mar	13-Mar	Serological					
96	Positive	Positive	08-Mar	16-Mar	Molecular					
101	Positive	Positive	07-Mar	08-Mar	Molecular					
103	Positive	Positive	07-Mar	08-Mar	Serological					
104	Positive	Equivocal	08-Mar	08-Mar	Serological					In case of a patient, sample 1B02/2018 is sent to confirmation by PCR, sample is positive.
106	Negative	Negative	15-Mar	16-Mar	Molecular					1B01/2018 is Positive in Exon 2 and Exon 3. 1B02/2018 is Positive in Exon 2 only and Negative in Exon 3
107	Positive	Positive	12-Mar	14-Mar	Molecular					
108	Positive	Positive	12-Mar	15-Mar	Molecular	Commercial	Gel			
109	Positive	Positive	07-Mar	09-Mar	Molecular					
110	Positive	Positive	07-Mar	07-Mar	Serological & Molecular					
111	Positive	Positive	07-Mar	08-Mar	Serological					
112	Positive	Positive	12-Mar	16-Mar	Molecular					
113	Positive	Positive	07-Mar	12-Mar	Molecular	Commercial	Gel			
115	Positive	Positive	12-Mar	12-Mar	Molecular	Commercial	Gel			
126	Positive	Positive	12-Mar	19-Mar	Molecular	Commercial	Fluorescence			
127	Positive	Positive	08-Mar	21-Mar	Molecular	Commercial	Luminescence			
128	Positive	Positive	07-Mar	22-Mar	Serological & Molecular	Commercial				By flow cytometry, the sample 1B02/2018 is negative
129	Positive	Positive	08-Mar	09-Mar	Molecular					
130	Positive	Positive	08-Mar	09-Mar	Serological & Molecular	Commercial	Gel			
133	Positive	Positive	07-Mar	12-Mar	Molecular					
137	Positive	Positive	07-Mar	13-Mar	Serological					
142	Positive	Positive	07-Mar	13-Mar	Molecular	Own design	Fluorescence			
150	Positive	Positive	08-Mar	08-Mar	Molecular					
153	Positive	Positive	07-Mar	08-Mar	Serological					
154	Positive	Positive	07-Mar	09-Mar	Molecular	Commercial	Gel			
156	Positive	Positive	08-Mar	12-Mar	Molecular	Own design	Fluorescence			
159	Positive	Positive	08-Mar	16-Mar	Molecular					
174	Positive	Positive	19-Mar	21-Mar	Molecular					
176	Positive	Positive	07-Mar	12-Mar	Molecular					
185	Positive	Positive	07-Mar	13-Mar	Molecular	Commercial	Gel	B*27:01-27:05.08, 27:05.10-27:05.15, 27:05.17-27:05.22, 27:05.24-27:05.32, 27:08/10/12-13/15-17/25/26/36, 27:09/24-27:05.32, 27:08/10/12-13/15-17/25/26/36, 40/42/44-45/47-49/71-74/78-80/82-84/86-27:90/03/92, 100/103-105/108-124/126/128/131-135/137/139/141-149/151-152/155-156		B*27:01-27:05.08, 27:05.10-27:05.15, 27:05.17-27:05.22, 27:05.24-27:05.32, 27:08/10/12-13/15-17/25/26/36, 27:09/24-27:05.32, 27:08/10/12-13/15-17/25/26/36, 40/42/44-45/47-49/71-74/78-80/82-84/86-27:90/03/92, 100/103-105/108-124/126/128/131-135/137/139/141-149/151-152/155-156
198	Positive	Positive	07-Mar	08-Mar	Serological					
209	Positive	Positive	07-Mar	08-Mar	Molecular					
219	Positive	Positive	14-Mar	16-Mar	Molecular					
223	Positive	Positive	14-Mar	14-Mar	Molecular	Commercial	Gel			
224	Positive	Positive	07-Mar	14-Mar	Molecular	Commercial	Gel			Coloured dots by substrate conversion on microchip
225	Positive	Positive	12-Mar	13-Mar	Molecular	Commercial	Gel			
232	Positive	Positive	10-Mar	13-Mar	Molecular	Commercial	Gel			
234	Positive	Positive	12-Mar	13-Mar	Molecular					
236	Positive	Positive	14-Mar	19-Mar	Serological					
245	Positive	Positive	07-Mar	12-Mar	Molecular					
252	Positive	Positive	05-Mar	19-Mar	Molecular	Commercial				
255	Positive	Positive	08-Mar	16-Mar	Molecular					
256	Negative	Negative	08-Mar	09-Mar	Serological					
257	Positive	Positive	07-Mar	14-Mar	Molecular					
269	Positive	Positive	14-Mar	15-Mar	Molecular					
273	Positive	Positive	07-Mar	08-Mar	Molecular					B*27:09
276	Positive	Positive	07-Mar	19-Mar	Molecular	Commercial	Melting point			
278	Positive	Positive	12-Mar	19-Mar	Molecular					Sample 1B01/2018 Positive exon 2 and exon 3 Sample 1B02/2018 only Positive exon 2
279	Negative	Negative	07-Mar	09-Mar	Serological					
288	Positive	Positive	07-Mar	07-Mar	Serological					
292	Positive	Positive	12-Mar	13-Mar	Serological					
295	Positive	Positive	07-Mar	07-Mar	Serological					
300	Positive	Positive	16-Mar	17-Mar	Molecular					
305	Positive	Positive	14-Mar	16-Mar	Molecular					
306	Positive	Positive	08-Mar	15-Mar	Molecular					
307	Positive	Positive	07-Mar	12-Mar	Molecular	Commercial	Fluorescence			
315	Positive	Positive	08-Mar	14-Mar	Molecular	Commercial	Fluorescence			
317	Positive	Positive	12-Mar	15-Mar	Molecular	Commercial	Tapestation (Agilent)/Gel			
319	Positive	Positive	07-Mar	08-Mar	Molecular					
324	Positive	Positive	14-Mar	14-Mar	Serological					
327	Positive	Positive	07-Mar	19-Mar	Molecular	Commercial	Gel			
334	Positive	Positive	08-Mar	08-Mar	Serological					
339	Positive	Positive	07-Mar	12-Mar	Molecular					
340	Positive	Positive	08-Mar	08-Mar	Molecular					
348	Positive	Equivocal	12-Mar	08-Mar	Serological					1B02/2018 was very degraded - non-interpretable result for this reason.
349	Positive	Positive	08-Mar	08-Mar	Serological					
353	Positive	Positive	08-Mar	19-Mar	Molecular					1B02/2018 is in the gray zone. Such results are confirmed by an alternate method.
357	Positive	Equivocal	09-Mar	09-Mar	Serological					This control is positive only in exon 2
359	Positive	Positive	08-Mar	15-Mar	Molecular					
362	Positive	Positive	08-Mar	15-Mar	Molecular					
365	Positive	Equivocal	08-Mar	08-Mar	Serological					
368	Positive	Positive	07-Mar	09-Mar	Molecular					In-house HLA-B27
372	Positive	Positive	12-Mar	13-Mar	Serological					
373	Positive	Positive	12-Mar	13-Mar	Serological					
377	Positive	Positive	09-Mar	12-Mar	Serological					
378	Positive	Positive	08-Mar	12-Mar	Serological					

UK NEQAS FOR H&I SCHEME 1B - HLA-B27 TESTING

HLA-B27 TYPING RESULTS OF SAMPLES 1B01&02/2018

DESPATCHED ON 06TH MARCH 2018

Lab No	Source of pos/neg control cells used (if applicable)	Monoclonal 1			Monoclonal 2			Monoclonal 3		
		Designation	Specificity	Manufacturer	Designation	Specificity	Manufacturer	Designation	Specificity	Manufacturer
20	In-house	Anti-B27-FITC/CD3-PE	B27+B7	BD	Anti-B27	B27	One Lambda	BB7.1 (unlabelled) CD45 PerCP-Cy5.5	HLA-B27	Beckman Coulter BD
67		UCHT1 (PE-Dyomics649)	CD3	Beckman Coulter	ABCm3 and FD705 (PE)	HLA-B27	Beckman Coulter			
128		Anti-B27 FITC		Beckman Coulter	Anti-B7 PE		Beckman Coulter			
137		GLA-ABCm3/BB7.1	HLA-B27/B7	Immunotech	FD705	HLA-B27	One Lambda			
324		HLA-B27-FITC	HLA-B27-FITC	Beckman Coulter	HLA-B7-PE	HLA-B7-PE	Beckman Coulter			
377	In-house	CD3 PE	100%	BD	HLA-B27	92%	BD			